Spun out of Fred Hutchinson Cancer Research Center, Seattle, WA and housed in CoMotion Labs at University of Washington, Chimerocyte is structured around development of molecular technologies to detect and quantify allogeneic cells and/or DNA at levels of sensitivity and specificity that are not reached by currently available techniques. The effort is to develop a highly sensitive quantitative chimerism test for use in clinical diagnostics and other scientific research. To date, (patent pending) work has yielded panel of several highly-sensitive and polymorphism-(HLA and other genes)-specific assays, with limit-of-detection reaching ?1:100,000. With transfer of the technology into a clinical application: chimerism monitoring post allo-transplantation, the company is extending development and validation of assays to detect and quantify allogeneic cells (chimerism) and evaluating the clinical significance of this technology for leukemia patients treated by allogeneic hematopoietic cell transplantation.